|
Market Closed -
Euronext Bruxelles
09:25:00 02/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 204.30 EUR | +1.49% |
|
-4.71% | -14.38% |
| 30/09 | Merck's experimental skin disease drug succeeds in mid-stage study | RE |
| 29/09 | UCB Presents Data From Innovative Myasthenia Gravis Portfolio At AANEM Annual Meeting And MGFA Scientific Session | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 4.38TCr | |||||
| 1,01900Cr | |||||
| 62TCr | - | ||||
| 46TCr | |||||
| 36TCr | |||||
| 33TCr |
- Stock Market
- Stocks
- UCB Stock
- Charts UCB
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
